Novel therapeutic strategies for metastatic prostate cancer in the post-docetaxel setting.

PubWeight™: 0.90‹?›

🔗 View Article (PMC 3233282)

Published in Oncologist on November 02, 2011


Oliver Sartor1, Ross M Michels, Christophe Massard, Johann Sebastian de Bono

Author Affiliations

1: Tulane Cancer Center, Tulane University, New Orleans, LA, USA.

Associated clinical trials:

Abiraterone Acetate in Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy | NCT00638690

Study of Immunotherapy to Treat Advanced Prostate Cancer | NCT00861614

Phase 3 Study of Immunotherapy to Treat Advanced Prostate Cancer | NCT01057810

Abiraterone Acetate in Asymptomatic or Mildly Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer | NCT00887198

Safety and Efficacy Study of MDV3100 in Patients With Castration-Resistant Prostate Cancer Who Have Been Previously Treated With Docetaxel-based Chemotherapy (AFFIRM) | NCT00974311

A Safety and Efficacy Study of Oral MDV3100 in Chemotherapy-Naive Patients With Progressive Metastatic Prostate Cancer (PREVAIL) | NCT01212991

Study Comparing Orteronel Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer | NCT01193257

A Phase III Study of Radium-223 Dichloride in Patients With Symptomatic Hormone Refractory Prostate Cancer With Skeletal Metastases (ALSYMPCA) | NCT00699751

Study Comparing Orteronel Plus Prednisone in Patients With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer | NCT01193244

Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate Cancer (SYNERGY) | NCT01188187

A Study Evaluating the Pain Palliation Benefit of Adding Custirsen to Docetaxel Retreatment or Cabazitaxel as Second Line Therapy in Men With Metastatic Castrate Resistant Prostate Cancer (mCRPC) | NCT01083615

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer (PROSELICA) | NCT01308580

Articles cited by this

Global cancer statistics. CA Cancer J Clin (2011) 185.92

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med (2004) 32.09

Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med (2010) 29.75

Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med (2011) 27.58

Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med (2004) 23.44

Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet (2010) 19.74

Molecular determinants of resistance to antiandrogen therapy. Nat Med (2003) 18.90

Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer (2002) 15.72

Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res (2008) 14.37

Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. J Clin Oncol (2008) 10.91

Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer. J Clin Oncol (2009) 6.68

Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance. Cancer Res (2008) 6.33

A novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth. Cancer Res (2009) 6.15

Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy. J Clin Oncol (2010) 6.04

Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate. J Clin Oncol (2010) 5.86

Duplication of the fusion of TMPRSS2 to ERG sequences identifies fatal human prostate cancer. Oncogene (2007) 4.81

Characterization of ERG, AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer. Cancer Res (2009) 4.68

Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer. J Clin Oncol (2010) 4.64

EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol (2011) 4.01

Novel steroidal inhibitors of human cytochrome P45017 alpha (17 alpha-hydroxylase-C17,20-lyase): potential agents for the treatment of prostatic cancer. J Med Chem (1995) 3.72

Starving the addiction: new opportunities for durable suppression of AR signaling in prostate cancer. Clin Cancer Res (2009) 3.61

Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II study. Lancet Oncol (2007) 3.51

Circulating tumour cell (CTC) counts as intermediate end points in castration-resistant prostate cancer (CRPC): a single-centre experience. Ann Oncol (2008) 3.44

Hormonal impact of the 17alpha-hydroxylase/C(17,20)-lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancer. Br J Cancer (2004) 3.32

Pharmacology of novel steroidal inhibitors of cytochrome P450(17) alpha (17 alpha-hydroxylase/C17-20 lyase). J Steroid Biochem Mol Biol (1994) 3.19

Anti-androgens and androgen-depleting therapies in prostate cancer: new agents for an established target. Lancet Oncol (2009) 3.13

Selective blockade of androgenic steroid synthesis by novel lyase inhibitors as a therapeutic strategy for treating metastatic prostate cancer. BJU Int (2005) 3.06

Antitumor activity with CYP17 blockade indicates that castration-resistant prostate cancer frequently remains hormone driven. Cancer Res (2009) 2.62

Expanding treatment options for metastatic prostate cancer. N Engl J Med (2011) 2.39

Phase I and pharmacokinetic study of XRP6258 (RPR 116258A), a novel taxane, administered as a 1-hour infusion every 3 weeks in patients with advanced solid tumors. Clin Cancer Res (2009) 2.30

A population pharmacokinetic model for docetaxel (Taxotere): model building and validation. J Pharmacokinet Biopharm (1996) 2.28

Drug insight: role of the androgen receptor in the development and progression of prostate cancer. Nat Clin Pract Oncol (2007) 2.09

Integration of ERG gene mapping and gene-expression profiling identifies distinct categories of human prostate cancer. BJU Int (2008) 1.88

Drug resistance in metastatic castration-resistant prostate cancer. Nat Rev Clin Oncol (2010) 1.86

Inhibition of the androgen receptor as a novel mechanism of taxol chemotherapy in prostate cancer. Cancer Res (2009) 1.80

A multicenter phase II study of XRP6258 administered as a 1-h i.v. infusion every 3 weeks in taxane-resistant metastatic breast cancer patients. Ann Oncol (2008) 1.80

Randomized phase II study of docetaxel and prednisone with or without OGX-011 in patients with metastatic castration-resistant prostate cancer. J Clin Oncol (2010) 1.76

Androgenic activity of synthetic progestins and spironolactone in androgen-sensitive mouse mammary carcinoma (Shionogi) cells in culture. J Steroid Biochem (1988) 1.60

CYP17 inhibition as a hormonal strategy for prostate cancer. Nat Clin Pract Urol (2008) 1.49

SIK2 is a centrosome kinase required for bipolar mitotic spindle formation that provides a potential target for therapy in ovarian cancer. Cancer Cell (2010) 1.42

Phase III trial of satraplatin, an oral platinum plus prednisone vs. prednisone alone in patients with hormone-refractory prostate cancer. Oncology (2005) 1.34

CYP17 blockade by abiraterone: further evidence for frequent continued hormone-dependence in castration-resistant prostate cancer. Br J Cancer (2009) 1.33

Camptothecin and taxol: discovery to clinic--thirteenth Bruce F. Cain Memorial Award Lecture. Cancer Res (1995) 1.27

Camptothecin and taxol: historic achievements in natural products research. J Nat Prod (2004) 1.26

Overview of dehydroepiandrosterone biosynthesis. Semin Reprod Med (2004) 1.20

Esters of 3-pyridylacetic acid that combine potent inhibition of 17 alpha-hydroxylase/C17,20-lyase (cytochrome P45017 alpha) with resistance to esterase hydrolysis. J Med Chem (1995) 1.15

Docetaxel reintroduction in patients with metastatic castration-resistant docetaxel-sensitive prostate cancer: a retrospective multicentre study. BJU Int (2010) 1.13

Overdiagnosis and overtreatment of early detected prostate cancer. World J Urol (2007) 1.05

Optimizing treatment for men with advanced prostate cancer: expert recommendations and the multidisciplinary approach. Crit Rev Oncol Hematol (2008) 0.93

Taxol resistance mediated by transfection of the liver-specific sister gene of P-glycoprotein. Cancer Res (1998) 0.88

Phase I dose-finding study of a new taxane, RPR 109881A, administered as a one-hour intravenous infusion days 1 and 8 to patients with advanced solid tumors. J Clin Oncol (2000) 0.87

Prostate cancer: moving forward by reinventing the wheel...but this time it is round. J Clin Oncol (2008) 0.86

Targeting the Androgen Receptor by Taxol in Castration-Resistant Prostate Cancer. Mol Cell Pharmacol (2010) 0.84

Should prostate-specific antigen screening be offered to asymptomatic men? Expert Rev Anticancer Ther (2010) 0.79

New agents in metastatic prostate cancer. Eur J Cancer (2009) 0.76

Articles by these authors

Tumor growth rate is an early indicator of antitumor drug activity in phase I clinical trials. Clin Cancer Res (2013) 2.06

Phase II study of dasatinib in patients with metastatic castration-resistant prostate cancer. Clin Cancer Res (2009) 1.99

Phase II trial of consolidation docetaxel and samarium-153 in patients with bone metastases from castration-resistant prostate cancer. J Clin Oncol (2009) 1.83

Brain metastases from breast carcinoma: validation of the radiation therapy oncology group recursive partitioning analysis classification and proposition of a new prognostic score. Int J Radiat Oncol Biol Phys (2007) 1.83

Conventional-dose versus high-dose chemotherapy as first salvage treatment in male patients with metastatic germ cell tumors: evidence from a large international database. J Clin Oncol (2011) 1.78

Prognostic factors in patients with metastatic germ cell tumors who experienced treatment failure with cisplatin-based first-line chemotherapy. J Clin Oncol (2010) 1.68

VEGF signalling inhibition-induced proteinuria: Mechanisms, significance and management. Eur J Cancer (2009) 1.45

Identifying the primary site using gene expression profiling in patients with carcinoma of an unknown primary (CUP): a feasibility study from the GEFCAPI. Onkologie (2012) 1.39

Multi-purpose utility of circulating plasma DNA testing in patients with advanced cancers. PLoS One (2012) 1.27

Hemangiopericytoma and antiangiogenic therapy: clinical benefit of antiangiogenic therapy (sorafenib and sunitinib) in relapsed malignant haemangioperyctoma /solitary fibrous tumour. Invest New Drugs (2009) 1.20

Sequential therapy in renal cell carcinoma. Cancer (2009) 1.18

Once-daily dasatinib: expansion of phase II study evaluating safety and efficacy of dasatinib in patients with metastatic castration-resistant prostate cancer. Urology (2011) 1.15

Tumor assessment criteria in phase I trials: beyond RECIST. J Clin Oncol (2012) 1.15

Inclusion of patients with advanced cancer in phase I trials: is this a tool for improving optimism and emotional well-being? J Clin Oncol (2013) 1.08

Tumour growth rates and RECIST criteria in early drug development. Eur J Cancer (2011) 1.00

Prediction of overall survival for patients with metastatic castration-resistant prostate cancer: development of a prognostic model through a crowdsourced challenge with open clinical trial data. Lancet Oncol (2016) 0.98

Drug insight: gastrointestinal and hepatic adverse effects of molecular-targeted agents in cancer therapy. Nat Clin Pract Oncol (2008) 0.97

Quantitative functional imaging by dynamic contrast enhanced ultrasonography (DCE-US) in GIST patients treated with masatinib. Invest New Drugs (2010) 0.95

The interval from the last cycle of docetaxel-based chemotherapy to progression is associated with the efficacy of subsequent docetaxel in patients with prostate cancer. Eur J Cancer (2010) 0.94

Targeted therapy-induced radiation recall. Eur J Cancer (2013) 0.94

Baseline circulating tumor cell counts significantly enhance a prognostic score for patients participating in phase I oncology trials. Clin Cancer Res (2011) 0.91

Brain metastases from breast cancer: proposition of new prognostic score including molecular subtypes and treatment. J Neurooncol (2011) 0.89

Minimal residual disease in solid neoplasia: New frontier or red-herring? Cancer Treat Rev (2011) 0.88

From theoretical synergy to clinical supra-additive toxicity. J Clin Oncol (2009) 0.88

Antiangiogenic agents and late anastomotic complications. J Surg Oncol (2010) 0.88

Prostate cancer: evolution or revolution? J Clin Oncol (2011) 0.87

Natural history, management and pharmacokinetics of everolimus-induced-oral ulcers: insights into compliance issues. Eur J Cancer (2011) 0.86

Accelerated MVAC chemotherapy in patients with advanced bladder cancer previously treated with a platinum-gemcitabine regimen. Eur J Cancer (2012) 0.85

Evaluation of sexuality, health-related quality-of-life and depression in advanced cancer patients: a prospective study in a Phase I clinical trial unit of predominantly targeted anticancer drugs. Eur J Cancer (2012) 0.85

Cardiac side effects of molecular targeted therapies: towards a better dialogue between oncologists and cardiologists. Crit Rev Oncol Hematol (2011) 0.84

Mitotic index and benefit of adjuvant anthracycline-based chemotherapy in patients with early breast cancer. J Clin Oncol (2005) 0.83

Brain metastases from breast cancer: prognostic significance of HER-2 overexpression, effect of trastuzumab and cause of death. BMC Cancer (2011) 0.83

ODM-201: a new-generation androgen receptor inhibitor in castration-resistant prostate cancer. Expert Rev Anticancer Ther (2015) 0.83

Reappraisal of treatment-induced renal dysfunction in patients receiving antiangiogenic agents in phase I trials. Invest New Drugs (2011) 0.83

A dose finding, safety and pharmacokinetic study of AVE1642, an anti-insulin-like growth factor-1 receptor (IGF-1R/CD221) monoclonal antibody, administered as a single agent and in combination with docetaxel in patients with advanced solid tumours. Eur J Cancer (2013) 0.82

Pitfalls and limitations of a single-centre, retrospectively derived prognostic score for phase I oncology trial participants - reply to Fussenich et al.: a new, simple and objective prognostic score for phase I cancer patients. Eur J Cancer (2011) 0.82

Changing therapeutic paradigms in castrate-resistant prostate cancer. Clin Genitourin Cancer (2010) 0.81

QT interval prolongation among patients treated with angiogenesis inhibitors. Target Oncol (2009) 0.81

Sunitinib inducing tumor lysis syndrome in a patient treated for renal carcinoma. Invest New Drugs (2009) 0.80

Vascular disrupting agents: a delicate balance between efficacy and side effects. Curr Opin Oncol (2012) 0.79

Implementing precision medicine initiatives in the clinic: a new paradigm in drug development. Curr Opin Oncol (2014) 0.79

Electrolyte disorders related to EGFR-targeting drugs. Crit Rev Oncol Hematol (2009) 0.78

Frequency and management of troponin I elevation in patients treated with molecular targeted therapies in phase I trials. Invest New Drugs (2010) 0.78

A risk-adapted strategy of radiotherapy or cisplatin-based chemotherapy in stage II seminoma. Urol Oncol (2011) 0.78

Targeted therapies in metastatic renal cell carcinoma: overview of the past year. Curr Urol Rep (2012) 0.78

Delivery by shock waves of active principle embedded in gelatin-based capsules. Ultrason Sonochem (2007) 0.77

Sorafenib plus dacarbazine in solid tumors: a phase I study with dynamic contrast-enhanced ultrasonography and genomic analysis of sequential tumor biopsy samples. Invest New Drugs (2013) 0.77

Trastuzumab-induced cardiotoxicity: is it time for troponin for all patients? Am J Clin Oncol (2012) 0.77

Reappraisal of the role of bevacizumab in the therapeutic strategy in advanced renal cell carcinoma. Clin Genitourin Cancer (2012) 0.77

[Locally advanced prostate cancer: definition, prognosis and treatment]. Bull Cancer (2007) 0.77

Combining functional imaging and interstitial pressure measurements to evaluate two anti-angiogenic treatments. Invest New Drugs (2010) 0.77

New agents in metastatic prostate cancer. Eur J Cancer (2009) 0.76

[American Society of Clinical Oncology (ASCO) 2011 essential data: the editorial board of the Bulletin du Cancer point of view]. Bull Cancer (2011) 0.76

Clinical benefit for patients with non-small cell lung cancer enrolled in phase I trials. Onkologie (2013) 0.76

[American Society of Clinical Oncology (ASCO) 2012 essential data: the editorial board of the Bulletin du Cancer point of view]. Bull Cancer (2012) 0.76

Toward a better dialogue between neuro-oncologists and phase I investigators. J Clin Oncol (2012) 0.75

[Prognostic factors for patients with brain metastases]. Bull Cancer (2013) 0.75

Phase I Dose-Escalation and Pharmacokinetic Study of Intravenous Aflibercept in Combination with Docetaxel, Cisplatin, and 5-Fluorouracil in Patients with Advanced Solid Malignancies. Oncology (2015) 0.75

[Cannabis and cancer]. Bull Cancer (2006) 0.75

Late recurrent testicular seminoma: histological evidence is required. Oncol Res Treat (2015) 0.75

[Nutrition and cancer: questions of balance]. Bull Cancer (2009) 0.75

[New hope in the treatment of advanced cancer of the prostate in 2012]. Bull Cancer (2012) 0.75

Acute left ventricular dysfunction induced by a panHER and VEGFR tyrosine kinase inhibitor in a phase I trial. Invest New Drugs (2009) 0.75

[Cell cycle, mitosis and therapeutic applications]. Bull Cancer (2011) 0.75

Wound healing delay after central venous access following DCF/VEGF-trap therapy. Invest New Drugs (2009) 0.75

False positive 2-(18)Fluroro-deoxy-D-glucose positron emission tomography (FDG-PET) in patients with disseminated seminoma and post-chemotherapy residual masses. Clin Genitourin Cancer (2012) 0.75

[A point on a new year]. Bull Cancer (2016) 0.75

[Brain metastases from breast cancer: usefulness and limits of prognostic scores]. Bull Cancer (2011) 0.75

[Bone targeted therapies: new agents]. Bull Cancer (2013) 0.75

Rhinitis in patients treated with a combination of an mTOR inhibitor and an EGFR inhibitor. Onkologie (2010) 0.75

[Bladder cancer. Editorial]. Bull Cancer (2010) 0.75

[Metronomic chemotherapy in 2011: update and perspectives]. Bull Cancer (2011) 0.75

[RB, guardian of prostatic tumor progression]. Bull Cancer (2011) 0.75

Proteinuria and proximal tubule lesions induced by an anti-integrin monoclonal antibody treatment: case report. Invest New Drugs (2009) 0.75

[Editorial]. Bull Cancer (2014) 0.75

Prognostic factors and outcome of patients with hematological malignancies in phase I trials: the Gustave Roussy scoring system. Anticancer Drugs (2017) 0.75